NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers
Latest Information Update: 14 Nov 2023
At a glance
- Drugs NTRX 07 (Primary)
- Indications Alzheimer's disease; Neuropathic pain
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors NeuroTherapia
Most Recent Events
- 01 Dec 2020 According to a NeuroTherapia media release, this study was supported by an Alzheimer's Association Part the Cloud grant.
- 01 Dec 2020 Results published in the NeuroTherapia Media Release.
- 01 Dec 2020 Status changed from active, no longer recruiting to completed, according to a NeuroTherapia media release.